| Species |
Mouse |
| Protein Construction |
B7-H3/CD276 (Val29-Ala248)
Accession # Q8VE98 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
24.98 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 42-52 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of B7-H3/CD276, His, Mouse is greater than 95% as determined by SEC-HPLC.
B7-H3/CD276, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
| Target Background |
B7-H3, a member of the B7 family of immunomodulatory molecules, is overexpressed in a wide range of solid cancers.B7-H3 binds to activated T cells via an as yet unidentified receptor. In assays using sub-optimal amount so anti-CD3 stimulation, 2Ig‑B7‑H3 enhances T cell proliferation, T cell interferon-gamma (IFN-gamma) production, and cytotoxic T cells induction. |
| Synonyms |
B7H3; B7-H3; CD276; PSEC0249; UNQ309; PRO352; B7 homolog 3; CD276 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
